2007 Press Releases
TSX:V - IXS
NASD OTC:BB: IXSBF
February 8, 2007
INNEXUS BIOTECHNOLOGY ANNOUNCES CHANGES TO THE BOARD OF DIRECTORS
British Columbia, Canada - February 8, 2007 - InNexus Biotechnology Inc., a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking technology is pleased to announce that Dr. Leroy Chiao, Mr. Laurence Luke and Mr. Wade Brooksby have joined the Board of Directors of the Company.
All three new directors bring unique and valuable experience to the management team of InNexus.
About InNexus
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of The Mayo Clinic and has its own in–house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward–looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.
Contact:
Jeff Morhet
President & Chief Executive Officer
InNexus Biotechnology Inc.
jmorhet@ixsbio.com
480-862-7500
